[Clinical research of crizotinib in advanced non-small cell lung cancer].

Abstract

At present, in the treatment of non-small cell lung cancer (NSCLC), targeted therapy has an important status. After epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKIs), crizotinib targeted at EML4-ALK fusion gene becomes a significant drug of molecular targeted therapy in NSCLC. Phase I and II clinical trials prove that crizotinib is effective for treatment of activating EML4-ALK mutation in advanced NSCLC patients, little side-effect, and well tolerated. Recently, crizotinib can inhibit ROS1 receptor tyrosine kinase and show extraordinary significant antitumor activity in ROS1-rearranged NSCLC. Drug resistance also exists in crizotinib. The mechanism of drug resistance needs further research. In this study, a review is performed in the mechanism and pharmacokinetics of crizotinib, and the clinical progress of treatment in advanced NSCLC.

DOI: 10.3779/j.issn.1009-3419.2013.06.09

Cite this paper

@article{Zhu2013ClinicalRO, title={[Clinical research of crizotinib in advanced non-small cell lung cancer].}, author={Haibo Zhu and Xiaoyu Xu and Ling Yun Wang}, journal={Zhongguo fei ai za zhi = Chinese journal of lung cancer}, year={2013}, volume={16 6}, pages={321-4} }